| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.086 | 0.1 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.079 | 0.1 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.46 | 0.1 |